HIV treatment response among female sex workers participating in a treatment as prevention demonstration project in Cotonou, Benin

Autoři: Mamadou Diallo aff001;  Luc Béhanzin aff002;  Fernand A. Guédou aff002;  Nassirou Geraldo aff003;  Ella Goma-Matsétsé aff003;  Dramane Kania aff005;  René Kpèmahouton Kêkê aff006;  Moussa Bachabi aff006;  Dissou Affolabi aff007;  Souleymane Diabaté aff001;  Flore Gangbo aff006;  Marcel Djimon Zannou aff007;  Michel Alary aff001
Působiště autorů: Département de médecine sociale et préventive, Université Laval, Québec aff001;  Axe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec–Université Laval, Québec, Canada aff002;  Dispensaire IST, Centre de santé communal de Cotonou 1, Cotonou, Bénin aff003;  Ecole Nationale de Formation des Techniciens Supérieurs en Santé Publique et en Surveillance Épidémiologique, Université de Parakou, Bénin aff004;  National Reference Laboratory of Viral Hemorrhagic Fever Centre MURAZ, Bobo-Dioulasso, Burkina Faso aff005;  Programme Santé de Lutte contre le Sida (PSLS), Cotonou, Bénin aff006;  Centre national hospitalier universitaire HMK de Cotonou, Bénin aff007;  Faculté des sciences de la santé, Université d’Abomey-Calavi, Cotonou, Bénin aff008;  Université Alassane Ouattara, Bouaké, Côte d’Ivoire aff009;  Institut national de santé publique du Québec, Québec, Canada aff010
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article



Female sex workers (FSWs) play a key role in HIV transmission in West Africa, while they have limited access to antiretroviral therapy (ART). In line with UNAIDS recommendations extending ART to all HIV-infected individuals, we conducted this demonstration project on immediate treatment as prevention (TasP) among FSWs in Cotonou, Benin. We report data on treatment response and its relation to adherence, as well as on ART-resistant genotypes.


Complete follow-up varied between 12 and 24 months. At each three-monthly visit, a questionnaire was administered, clinical examinations were carried out and blood samples collected. Adherence to treatment was estimated by self-report. Viral RNA was genotyped at baseline and final visits for drug resistance. Generalized estimating equations for repeated measures with a log-binomial link were used to analyze time trends and the association between adherence and virological response to treatment.


One-hundred-seven HIV-positive and ART-naive FSWs were enrolled; 59.8% remained in the cohort till study completion and 62.6% had a final visit. Viral load<1000 (below quantification limit [<50]) was attained in 73.1% (64.6%) of participants at month-6, 84.8% (71.2%) at month-12, and 80.9% (65.1%) at the final visit. The proportion of women with suppressed (below quantification limit) viral load increased with increasing self-reported adherence (p = 0.06 (0.003), tests for trend). The proportion of participants with CD4≤500 also decreased drastically throughout follow-up (p < .0001). Twelve participants exhibited ART-resistant genotypes at baseline, but only two at their final visit.


Our findings indicate that TasP is widely accepted among FSWs in Cotonou and could be implemented with relative success. However, due to mobility in this population, follow-up was sub-optimal, suggesting that large geographical coverage of FSW-friendly clinics is needed for sustained treatment implementation. We also fell short of the UNAIDS objective of 90% viral suppression among treated patients, underlining the need for better adherence support programs.

Klíčová slova:

Antimicrobial resistance – Antiretroviral therapy – Benin – Female sex workers – HIV epidemiology – HIV prevention – Sex work – Viral load


1. UNAIDS (2017). UNAIDS data-book_2017. Last Aaccessed 20 July 2019.

2. UNAIDS Regional factsheets Africa, West and Central. accessed 31st May 2018

3. Boily MC, Pickles M, Alary M, Baral S, Blanchard J, Moses S, et al. What really is a concentrated HIV epidemic and what does it mean for West and Central Africa? Insights from mathematical modeling. J Acquir Immune Defic Syndr. 2015;68 Suppl 2:S74–82. Epub 2015/02/28. doi: 10.1097/qai.0000000000000437 25723994.

4. Mishra S, Sgaier SK, Thompson LH, Moses S, Ramesh BM, Alary M, et al. HIV epidemic appraisals for assisting in the design of effective prevention programmes: shifting the paradigm back to basics. PLoS One. 2012;7(3):e32324. Epub 2012/03/08. doi: 10.1371/journal.pone.0032324 22396756; PubMed Central PMCID: PMC3291609.

5. Mishra S, Pickles M, Blanchard JF, Moses S, Shubber Z, Boily MC. Validation of the modes of transmission model as a tool to prioritize HIV prevention targets: a comparative modelling analysis. PLoS One. 2014;9(7):e101690. Epub 2014/07/12. doi: 10.1371/journal.pone.0101690 25014543; PubMed Central PMCID: PMC4090151.

6. Nagot N, Ouangre A, Ouedraogo A, Cartoux M, Huygens P, Defer MC, et al. Spectrum of commercial sex activity in Burkina Faso: classification model and risk of exposure to HIV. J Acquir Immune Defic Syndr. 2002;29(5):517–21. Epub 2002/05/01. doi: 10.1097/00126334-200204150-00013 11981369.

7. Lowndes CM, Alary M, Meda H, Gnintoungbe CA, Mukenge-Tshibaka L, Adjovi C, et al. Role of core and bridging groups in the transmission dynamics of HIV and STIs in Cotonou, Benin, West Africa. Sex Transm Infect. 2002;78 Suppl 1:i69–77. Epub 2002/06/27. doi: 10.1136/sti.78.suppl_1.i69 12083450; PubMed Central PMCID: PMC1765827.

8. Alary M, Lowndes CM. The central role of clients of female sex workers in the dynamics of heterosexual HIV transmission in sub-Saharan Africa. AIDS. 2004;18(6):945–7. Epub 2004/04/03. doi: 10.1097/00002030-200404090-00013 15060443.

9. Global report: UNAIDS report on the global AIDS epidemic 2013. › sites › default › files › media_asset › UNAIDS_Glo. Last accessed 18 April 2018

10. Labbe AC, Pepin J, Khonde N, Dzokoto A, Meda H, Asamoah-Adu C, et al. Periodical antibiotic treatment for the control of gonococcal and chlamydial infections among sex workers in Benin and Ghana: a cluster-randomized placebo-controlled trial. Sex transm dis. 2012;39(4):253–9. Epub 2012/03/17. doi: 10.1097/OLQ.0b013e318244aaa0 22421690.

11. Sobela F, Pepin J, Gbeleou S, Banla AK, Pitche VP, Adom W, et al. A tale of two countries: HIV among core groups in Togo. J Acquir Immune Defic Syndr. 2009;51(2):216–23. Epub 2009/04/03. doi: 10.1097/QAI.0b013e31819c170f 19339896.

12. Prüss-Ustün A, Wolf J, Driscoll T, Degenhardt L, Neira M, Calleja JM.HIV due to female sex work: regional and global estimates. PLoS One. 2013 May 23; 8(5):e63476. doi: 10.1371/journal.pone.0063476 Print 2013. 23717432

13. Moses S, Ramesh BM, Nagelkerke NJ, Khera A, Isac S, Bhattacharjee P, et al. Impact of an intensive HIV prevention programme for female sex workers on HIV prevalence among antenatal clinic attenders in Karnataka state, south India: an ecological analysis. AIDS. 2008;22 Suppl 5:S101–8. Epub 2009/01/07. doi: 10.1097/01.aids.0000343768.85325.92 19098470.

14. Kane CT, Diawara S, Ndiaye HD, Diallo PA, Wade AS, Diallo AG, et al. Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV. Int J STD AIDS. 2009;20(11):793–6. Epub 2009/10/31. doi: 10.1258/ijsa.2008.008414 19875833.

15. Diabaté S, Zannou DM, Geraldo N, Chamberland A, Akakpo J, Ahouada C, et al. Antiretroviral Therapy among HIV-1 Infected Female Sex Workers in Benin: A Comparative Study with Patients from the General Population. World J AIDS. 2011;01(03):94–9. doi: 10.4236/wja.2011.13014

16. Diabate S, Chamberland A, Zannou DM, Geraldo N, Azon-Kouanou A, Massinga-Loembe M, et al. Sexual behaviour after antiretroviral therapy initiation in female sex workers and HIV-positive patients from the general population, Cotonou, Benin. AIDS Care. 2013;25(11):1426–32. Epub 2013/02/27. doi: 10.1080/09540121.2013.772279 23438011.

17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Epub 2011/07/20. doi: 10.1056/NEJMoa1105243 21767103; PubMed Central PMCID: PMC3200068.

18. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Eng J Med. 2012;367(5):399–410. Epub 2012/07/13. doi: 10.1056/NEJMoa1108524 22784037; PubMed Central PMCID: PMC3770474.

19. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Eng J Med. 2012;367(5):423–34. Epub 2012/07/13. doi: 10.1056/NEJMoa1110711 22784038.

20. Mboup A, Béhanzin L, Guédou FA, Geraldo N, Goma-Matsétsé E, Giguère K, et al. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. J Int AIDS Soc. 2018;21(11). doi: 10.1002/jia2.25208 31291057

21. Rodes B, Sheldon J, Toro C, Cuevas L, Perez-Pastrana E, Herrera I, et al. Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1). J Clin Microbiol. 2007;45(1):88–92. doi: 10.1128/JCM.01613-06 17093034; PubMed Central PMCID: PMC1828987.

22. ANRS Resistance Study Group. PCR and Sequencing Procedures. http//www.hivfrenchresistance.orgANRS-procedures.pdf. Last accessed 16 May 2017

23. Standford Surveillance Drug Resistance Mutation (SDRM) Worksheet NRTI_Pheno Summary.pdf. Last accessed 16 May 2017

24. ANRS—AC 11; HIV genotypic drug resistance interpretation’s algorythms NNRTIs.pdf. Last accessed 16 May 2017

25. Standford Surveillance Drug Resistance Mutation (SDRM) Worksheet NNRTI_PhenoSummary.pdf. Last accessed 16 May 2017

26. Van Laethem K, Geretti AM, Camacho R. and Vandamme AM. Algorithm for the use of genotypic HIV-1 resistance data Rega_HIV1_Rules_v8.0.2.pdf. › cev › avd › software › rega-a. Last accessed accessed 16 June 2018

27. World Health Organization(2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection.pdf. Last accessed 25 April2018

28. Consolidated guidelines on the use of antiretroviral drugs for treating and Preventing HIV infection. Recommendations for a public health approach. Second edition. 2016. › iris › handle. Last accessed 25 April2018

29. République du Bénin, Enquête de surveillance de deuxième génération relative aux IST, VIH et Sida au Bénin (ESDG-2015).pdf.

30. UNAIDS (2014). 90-90-90 an ambitious treatment targets to help end the AIDS epidemic.pdf. › resources › 909090. Last accessed 26 May 2018

31. Vuylsteke B, Semde G, Auld AF, Sabatier J, Kouakou J, Ettiegne-Traore V, et al. Retention and risk factors for loss to follow-up of female and male sex workers on antiretroviral treatment in Ivory Coast: a retrospective cohort analysis. J Acquir Immune Defic Syndr. 2015;68 Suppl 2:S99–S106. Epub 2015/02/28. doi: 10.1097/qai.0000000000000442 25723997.

32. Wang H, Chen RY, Sharp GB, Brown K, Smith K, Ding G, et al. Mobility, risk behavior and HIV/STI rates among female sex workers in Kaiyuan City, Yunnan Province, China. BMC infect dis. 2010;10:198. Epub 2010/07/10. doi: 10.1186/1471-2334-10-198 20615260; PubMed Central PMCID: PMC2914052.

33. Ramesh S, Ganju D, Mahapatra B, Mishra RM, Saggurti N. Relationship between mobility, violence and HIV/STI among female sex workers in Andhra Pradesh, India. BMC Public Health. 2012;12:764. Epub 2012/09/13. doi: 10.1186/1471-2458-12-764 22967276; PubMed Central PMCID: PMC3490918.

34. Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, et al. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project. PLoS Med. 2017;14(11):e1002444. Epub 2017/11/22. doi: 10.1371/journal.pmed.1002444 29161256; PubMed Central PMCID: PMC5697804.

35. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65. Epub 2007/05/17. doi: 10.1080/09540120701244943 17505927.

36. Mtetwa S, Busza J, Chidiya S, Mungofa S, Cowan F. "You are wasting our drugs": health service barriers to HIV treatment for sex workers in Zimbabwe. BMC Public Health. 2013;13:698. Epub 2013/08/01. doi: 10.1186/1471-2458-13-698 23898942; PubMed Central PMCID: PMC3750331.

37. Cowan FM, Davey CB, Fearon E, Mushati P, Dirawo J, Cambiano V, et al. The HIV Care Cascade Among Female Sex Workers in Zimbabwe: Results of a Population-Based Survey From the Sisters Antiretroviral Therapy Programme for Prevention of HIV, an Integrated Response (SAPPH-IRe) Trial. J Acquir Immune Defic Syndr. 2017;74(4):375–82. Epub 2016/12/09. doi: 10.1097/QAI.0000000000001255 27930599.

38. Graham SM, Masese L, Gitau R, Jalalian-Lechak Z, Richardson BA, Peshu N, et al. Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis. 2010;202(10):1538–42. Epub 2010/10/07. doi: 10.1086/656790 20923373; PubMed Central PMCID: PMC2957525.

39. Mountain E, Mishra S, Vickerman P, Pickles M, Gilks C, Boily MC. Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV-infected female sex workers: a systematic review and meta-analysis. PLoS One. 2014;9(9):e105645. doi: 10.1371/journal.pone.0105645 25265158; PubMed Central PMCID: PMC4179256.

40. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316(2):171–81. Epub 2016/07/13. doi: 10.1001/jama.2016.5148 27404185.

41. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375(9):830–9. Epub 2016/07/19. doi: 10.1056/NEJMoa1600693 27424812; PubMed Central PMCID: PMC5049503.

42. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–60. Epub 1998/03/27. doi: 10.1056/NEJM199803263381301 9516219.

43. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18(1):45–9. Epub 2004/04/20. doi: 10.1097/00002030-200401020-00005 15090828.

44. Chamberland A, Diabate S, Sylla M, Anagounou S, Geraldo N, Zannou DM, et al. Transmission of HIV-1 drug resistance in Benin could jeopardise future treatment options. Sex Transm Infect. 2012;88(3):179–83. Epub 2011/12/14. doi: 10.1136/sextrans-2011-050209 22158948.

Článek vyšel v časopise


2020 Číslo 1
Nejčtenější tento týden